METTL14 and acute myeloid leukemia: Our study showed that METTL3 and METTL14 are highly expressed in patients with AML (except APL), and high levels of METTL3 and METTL14 correlate to shorter survival, indicating that METTL3 and METTL14 are adverse factors in patients with AML.